Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma

David P. Mangiameli, Joseph A. Blansfield, Stephan Kachala, Dominique Lorang, Peter H. Schafer, George W. Muller, David I. Stirling, Steven K. Libutti

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Ocular melanoma is the leading intraocular malignancy. There is no effective treatment for metastatic ocular melanoma. We sought a treatment targeting the tumor microenvironment as well as the tumor cells. Methods: Migration of HUVEC cells, the ability of HUVEC cells toform tubes, and proliferative capacity of a human ocular melanoma cell line were tested in the presence of lenalidomide and sorafenib alone and in combination. The compounds were also tested in a rat aortic ring assay and were tested in a highly aggressive human ocular melanoma xenograft model. Results: Lenalidomide and Sorafenib inhibit HUVEC ability to migrate and form tubes and when used in combination the inhibition is increased. The agents alone and in combination inhibit outgrowth in the rat aortic ring model. The combination of the agents improved the inhibition over either single agent. In a xenograft model, combination therapy inhibited tumor growth over inhibition by single agent alone in a significant fashion (p < 0.004: lenalidomide and p < 0.0035: sorafenib). Furthermore, spontaneous lung metastasis development was completely inhibited in the combination treated animals. Sixty percent of vehicle treated animals developed lung metastases compared to 50% of lenalidomide treated animals, and 33% of sorafenib treated animals. Conclusion: Lenalidomide and sorafenib are effective at targeting endothelial cells, inhibiting growth of ocular melanoma cells and can inhibit growth of tumors in a xenograft model as well as inhibit development of metastases. Combining these agents works in an additive to synergistic way to inhibit the growth of tumors and development of metastases.

Original languageEnglish (US)
Article number38
JournalJournal of Translational Medicine
Volume5
DOIs
StatePublished - Jul 18 2007
Externally publishedYes

Fingerprint

Tumor Microenvironment
Tumors
Melanoma
Animals
Heterografts
Neoplasm Metastasis
Human Umbilical Vein Endothelial Cells
Neoplasms
Rats
Growth
Cells
Therapeutics
Lung
Endothelial cells
Cell growth
Growth and Development
Assays
Endothelial Cells
lenalidomide
sorafenib

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Mangiameli, D. P., Blansfield, J. A., Kachala, S., Lorang, D., Schafer, P. H., Muller, G. W., ... Libutti, S. K. (2007). Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. Journal of Translational Medicine, 5, [38]. https://doi.org/10.1186/1479-5876-5-38

Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. / Mangiameli, David P.; Blansfield, Joseph A.; Kachala, Stephan; Lorang, Dominique; Schafer, Peter H.; Muller, George W.; Stirling, David I.; Libutti, Steven K.

In: Journal of Translational Medicine, Vol. 5, 38, 18.07.2007.

Research output: Contribution to journalArticle

Mangiameli, DP, Blansfield, JA, Kachala, S, Lorang, D, Schafer, PH, Muller, GW, Stirling, DI & Libutti, SK 2007, 'Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma', Journal of Translational Medicine, vol. 5, 38. https://doi.org/10.1186/1479-5876-5-38
Mangiameli, David P. ; Blansfield, Joseph A. ; Kachala, Stephan ; Lorang, Dominique ; Schafer, Peter H. ; Muller, George W. ; Stirling, David I. ; Libutti, Steven K. / Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. In: Journal of Translational Medicine. 2007 ; Vol. 5.
@article{9b992e64bc294bbaa83cfb12470255ea,
title = "Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma",
abstract = "Background: Ocular melanoma is the leading intraocular malignancy. There is no effective treatment for metastatic ocular melanoma. We sought a treatment targeting the tumor microenvironment as well as the tumor cells. Methods: Migration of HUVEC cells, the ability of HUVEC cells toform tubes, and proliferative capacity of a human ocular melanoma cell line were tested in the presence of lenalidomide and sorafenib alone and in combination. The compounds were also tested in a rat aortic ring assay and were tested in a highly aggressive human ocular melanoma xenograft model. Results: Lenalidomide and Sorafenib inhibit HUVEC ability to migrate and form tubes and when used in combination the inhibition is increased. The agents alone and in combination inhibit outgrowth in the rat aortic ring model. The combination of the agents improved the inhibition over either single agent. In a xenograft model, combination therapy inhibited tumor growth over inhibition by single agent alone in a significant fashion (p < 0.004: lenalidomide and p < 0.0035: sorafenib). Furthermore, spontaneous lung metastasis development was completely inhibited in the combination treated animals. Sixty percent of vehicle treated animals developed lung metastases compared to 50{\%} of lenalidomide treated animals, and 33{\%} of sorafenib treated animals. Conclusion: Lenalidomide and sorafenib are effective at targeting endothelial cells, inhibiting growth of ocular melanoma cells and can inhibit growth of tumors in a xenograft model as well as inhibit development of metastases. Combining these agents works in an additive to synergistic way to inhibit the growth of tumors and development of metastases.",
author = "Mangiameli, {David P.} and Blansfield, {Joseph A.} and Stephan Kachala and Dominique Lorang and Schafer, {Peter H.} and Muller, {George W.} and Stirling, {David I.} and Libutti, {Steven K.}",
year = "2007",
month = "7",
day = "18",
doi = "10.1186/1479-5876-5-38",
language = "English (US)",
volume = "5",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma

AU - Mangiameli, David P.

AU - Blansfield, Joseph A.

AU - Kachala, Stephan

AU - Lorang, Dominique

AU - Schafer, Peter H.

AU - Muller, George W.

AU - Stirling, David I.

AU - Libutti, Steven K.

PY - 2007/7/18

Y1 - 2007/7/18

N2 - Background: Ocular melanoma is the leading intraocular malignancy. There is no effective treatment for metastatic ocular melanoma. We sought a treatment targeting the tumor microenvironment as well as the tumor cells. Methods: Migration of HUVEC cells, the ability of HUVEC cells toform tubes, and proliferative capacity of a human ocular melanoma cell line were tested in the presence of lenalidomide and sorafenib alone and in combination. The compounds were also tested in a rat aortic ring assay and were tested in a highly aggressive human ocular melanoma xenograft model. Results: Lenalidomide and Sorafenib inhibit HUVEC ability to migrate and form tubes and when used in combination the inhibition is increased. The agents alone and in combination inhibit outgrowth in the rat aortic ring model. The combination of the agents improved the inhibition over either single agent. In a xenograft model, combination therapy inhibited tumor growth over inhibition by single agent alone in a significant fashion (p < 0.004: lenalidomide and p < 0.0035: sorafenib). Furthermore, spontaneous lung metastasis development was completely inhibited in the combination treated animals. Sixty percent of vehicle treated animals developed lung metastases compared to 50% of lenalidomide treated animals, and 33% of sorafenib treated animals. Conclusion: Lenalidomide and sorafenib are effective at targeting endothelial cells, inhibiting growth of ocular melanoma cells and can inhibit growth of tumors in a xenograft model as well as inhibit development of metastases. Combining these agents works in an additive to synergistic way to inhibit the growth of tumors and development of metastases.

AB - Background: Ocular melanoma is the leading intraocular malignancy. There is no effective treatment for metastatic ocular melanoma. We sought a treatment targeting the tumor microenvironment as well as the tumor cells. Methods: Migration of HUVEC cells, the ability of HUVEC cells toform tubes, and proliferative capacity of a human ocular melanoma cell line were tested in the presence of lenalidomide and sorafenib alone and in combination. The compounds were also tested in a rat aortic ring assay and were tested in a highly aggressive human ocular melanoma xenograft model. Results: Lenalidomide and Sorafenib inhibit HUVEC ability to migrate and form tubes and when used in combination the inhibition is increased. The agents alone and in combination inhibit outgrowth in the rat aortic ring model. The combination of the agents improved the inhibition over either single agent. In a xenograft model, combination therapy inhibited tumor growth over inhibition by single agent alone in a significant fashion (p < 0.004: lenalidomide and p < 0.0035: sorafenib). Furthermore, spontaneous lung metastasis development was completely inhibited in the combination treated animals. Sixty percent of vehicle treated animals developed lung metastases compared to 50% of lenalidomide treated animals, and 33% of sorafenib treated animals. Conclusion: Lenalidomide and sorafenib are effective at targeting endothelial cells, inhibiting growth of ocular melanoma cells and can inhibit growth of tumors in a xenograft model as well as inhibit development of metastases. Combining these agents works in an additive to synergistic way to inhibit the growth of tumors and development of metastases.

UR - http://www.scopus.com/inward/record.url?scp=34547925624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547925624&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-5-38

DO - 10.1186/1479-5876-5-38

M3 - Article

C2 - 17640369

AN - SCOPUS:34547925624

VL - 5

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

M1 - 38

ER -